Food and Drug Administration (FDA) has agreed to the first new type of pain relievers in decades

For acute pain, doctors in the United States usually prescribe opioids: strong pain relievers with dangerous side effects including danger of serious addiction and overdose. Now, the US Food and Drug Administration (FDA) led to promising alternative lighting: a new non -audio pain.

The Food and Drug Administration (FDA) has agreed to a new type of drug called Suzetrigine, Journavx, to treat acute pain in adults without the risk of addiction. Suzetrigine is the first new category of pain medicine approved by the agency in more than two decades, as well as the first of its kind -based drug. The advertisement represents a great milestone in developing the most secure pain management, as is detailed in a statement The Food and Drug Administration (FDA) was released yesterday.

“This is an incredible day for both patients and doctors who now have an approved non -opioid treatment that provides an effective relief of acute pain and a favorable safety profile without the possibility of addiction,” said Jessica Oswald, a member of the acute head -up committee at the top of the head. At the top of the head statement. Vertex Pharmaceuticals is a Boston -based biotechnology company that has recently developed the newly approved drug.

“I think JournaVX can redefine pain management and become an option for founding treatment for people who have all kinds of moderate to severe acute pain, as there was an urgent need for options of opiates.” Since 1999, hundreds of thousands of Americans He died from an overdose of opiates. Despite the epidemic, doctors extracted in the United States 125 million Apionian recipes In 2023 alone.

Opioid Activating receptors in the brain To prevent pain signals and cause release EndorphinsThe body feels satisfied, Natural pain relievers– This is why we risk destroy. On the other hand, suzetrigine prevent sodium channels on the neurons sensor, which prevents the pain signal from reaching the brain in the first place, and does not give any “high”. It is prescribed as “effective” and “well -endowed”, according to Vertex.

“It was mentioned by NBC News. “It is not different from Tylinol or ibuprofen in terms of addiction.”

Tue Vairin, who participated in a 2023 clinical trial for medicine after undergoing nose surgery, told. nature She “felt very clear” after taking the medicine, and did not suffer from side effects associated with opioid drugs such as nausea or nausea.

“The approval of today is a historical sign,” said Rishma Kiwalmani, CEO of Vertex and President in VERTEX. “We have the opportunity to change the acute pain management model and set up a new level of care.”

However, given the acute price of the drug-$ 15.50 per grain of 50 milligrams-it remains to see whether suzetrigine has practical potential, as well as a medical alternative, to become a wide alternative.